BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 33070952)

  • 1. [European approvals: Glasdegib for Acute myeloid leukemia].
    Barrière S; Gastaud L
    Bull Cancer; 2020 Dec; 107(12):1206-1207. PubMed ID: 33070952
    [No Abstract]   [Full Text] [Related]  

  • 2. New drugs approved for acute myeloid leukaemia in 2018.
    Kucukyurt S; Eskazan AE
    Br J Clin Pharmacol; 2019 Dec; 85(12):2689-2693. PubMed ID: 31469910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glasdegib: First Global Approval.
    Hoy SM
    Drugs; 2019 Feb; 79(2):207-213. PubMed ID: 30666593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent drug approvals for newly diagnosed acute myeloid leukemia: gifts or a Trojan horse?
    Estey E; Karp JE; Emadi A; Othus M; Gale RP
    Leukemia; 2020 Mar; 34(3):671-681. PubMed ID: 31915366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute myeloid leukemia: How to treat the fit patient over age 75?
    Luger SM
    Best Pract Res Clin Haematol; 2019 Dec; 32(4):101105. PubMed ID: 31779985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [New therapeutic agents for acute myeloid leukemia].
    Hosono N
    Rinsho Ketsueki; 2019; 60(9):1108-1119. PubMed ID: 31597834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in non-intensive chemotherapy treatment options for adults diagnosed with acute myeloid leukemia.
    Griffiths EA; Carraway HE; Chandhok NS; Prebet T
    Leuk Res; 2020 Apr; 91():106339. PubMed ID: 32146154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Venetoclax-based therapies for acute myeloid leukemia.
    Guerra VA; DiNardo C; Konopleva M
    Best Pract Res Clin Haematol; 2019 Jun; 32(2):145-153. PubMed ID: 31203996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An evaluation of glasdegib for the treatment of acute myelogenous leukemia.
    Thomas X; Heiblig M
    Expert Opin Pharmacother; 2020 Apr; 21(5):523-530. PubMed ID: 32027196
    [No Abstract]   [Full Text] [Related]  

  • 10. Glasdegib for the treatment of adult patients with newly diagnosed acute myeloid leukemia or high-grade myelodysplastic syndrome who are elderly or otherwise unfit for standard induction chemotherapy.
    Goldsmith SR; Lovell AR; Schroeder MA
    Drugs Today (Barc); 2019 Sep; 55(9):545-562. PubMed ID: 31584572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Highlights in Hematologic Malignancy Treatments: Leukemia, Myelodysplastic Syndromes, and Allotransplant-New Drugs on the Horizon for Acute Myeloid Leukemia.
    Jurcic JG
    JAMA Oncol; 2017 Mar; 3(3):299-300. PubMed ID: 27787556
    [No Abstract]   [Full Text] [Related]  

  • 12. Drug-drug interactions of newly approved small molecule inhibitors for acute myeloid leukemia.
    Megías-Vericat JE; Solana-Altabella A; Ballesta-López O; Martínez-Cuadrón D; Montesinos P
    Ann Hematol; 2020 Sep; 99(9):1989-2007. PubMed ID: 32683457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. <Editors' Choice> How to improve outcomes of elderly patients with acute myeloid leukemia: era of excitement.
    Naoe T
    Nagoya J Med Sci; 2020 May; 82(2):151-160. PubMed ID: 32581396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glasdegib for the treatment of acute myeloid leukemia.
    Bruzzese A; Martino EA; Labanca C; Mendicino F; Lucia E; Olivito V; Fimognari F; Neri A; Morabito F; Vigna E; Gentile M
    Expert Opin Pharmacother; 2023; 24(14):1537-1543. PubMed ID: 37392098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FDA Approval Summary: Glasdegib for Newly Diagnosed Acute Myeloid Leukemia.
    Norsworthy KJ; By K; Subramaniam S; Zhuang L; Del Valle PL; Przepiorka D; Shen YL; Sheth CM; Liu C; Leong R; Goldberg KB; Farrell AT; Pazdur R
    Clin Cancer Res; 2019 Oct; 25(20):6021-6025. PubMed ID: 31064779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AML: New Drugs but New Challenges.
    Burnett A; Stone R
    Clin Lymphoma Myeloma Leuk; 2020 Jun; 20(6):341-350. PubMed ID: 32151586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Venetoclax combined with azacitidine in the treatment of elderly patients with acute myeloid leukemia or myeloid sarcoma: Three cases reports and literature review].
    Tian FQ; Zhang LS; Li JH; Tang MQ; Jiang J; Cheng XH; Zhang XC; Jiang M
    Zhonghua Xue Ye Xue Za Zhi; 2020 Aug; 41(8):694-696. PubMed ID: 32942828
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy and predictive factors of venetoclax combined with azacitidine as salvage therapy in advanced acute myeloid leukemia patients: A multicenter retrospective study.
    Lou Y; Shao L; Mao L; Lu Y; Ma Y; Fan C; Jiang H; Li J; Jin J
    Leuk Res; 2020 Apr; 91():106317. PubMed ID: 32092584
    [No Abstract]   [Full Text] [Related]  

  • 19. Acute myeloid leukemia drug development in the post-venetoclax era.
    Pollyea DA
    Am J Hematol; 2019 Sep; 94(9):959-962. PubMed ID: 31179583
    [No Abstract]   [Full Text] [Related]  

  • 20. New directions for emerging therapies in acute myeloid leukemia: the next chapter.
    Daver N; Wei AH; Pollyea DA; Fathi AT; Vyas P; DiNardo CD
    Blood Cancer J; 2020 Oct; 10(10):107. PubMed ID: 33127875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.